Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group
详细信息 查看全文
- 作者：Mari Sakai (1)
Yasushi Miyazaki (1)
Emi Matsuo (1)
Yukiyoshi Moriuchi (2)
Tomoko Hata (1)
Takuya Fukushima (1)
Yoshitaka Imaizumi (1)
Daisuke Imanishi (1)
Jun Taguchi (1)
Masako Iwanaga (1)
Hideki Tsushima (2)
Yoriko Inoue (2)
Yumi Takasaki (2)
Takeshi Tsuchiya (1)
Minori Komoda (1)
Koji Ando (1)
Kensuke Horio (1)
Yuji Moriwaki (2)
Shinya Tominaga (1)
Hidehiro Itonaga (1)
Kazuhiro Nagai (1)
Kunihiro Tsukasaki (1)
Chizuko Tsutsumi (2)
Yasushi Sawayama (2)
Reishi Yamasaki (2)
Daisuke Ogawa (2)
Yasuhisa Kawaguchi (2)
Shuichi Ikeda (2)
Shinichiro Yoshida (2)
Yasuyuki Onimaru (2)
Masayuki Tawara (2)
Sunao Atogami (2)
Satoshi Koida (2)
Tatsuro Joh (2)
Masaomi Yamamura (2)
Yuji Matsuo (2)
Hisashi Soda (2)
Hiroaki Nonaka (2)
Itsuro Jinnai (2)
Kazutaka Kuriyama (2)
Masao Tomonaga (1) - 关键词：CML ; Imatinib ; Trough concentration
- 刊名：International Journal of Hematology
- 出版年：2009
- 出版时间：April 2009
- 年：2009
- 卷：89
- 期：3
- 页码：319-325
- 全文大小：278KB
- 参考文献：1. Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet. Chronic myeloid leukaemia. Lancet. 2007;370:342-0. doi:10.1016/S0140-6736(07)61165-9 . CrossRef
2. Borthakur G, Cortes JE. Imatinib mesylate treat chronic myelogenous leukemia. Int J Hematol. 2004;79:411-. CrossRef
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-3. doi:10.1182/blood-2004-08-3097 . CrossRef
4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-004. doi:10.1056/NEJMoa022457 . CrossRef
5. Hughes TM, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-2. doi:10.1056/NEJMoa030513 . CrossRef
6. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-7. doi:10.1056/NEJMoa062867 . CrossRef
7. Matsuo E, Miyazaki Y, Tsutsumi C, Inoue Y, Yamasaki R, Hata T, et al. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in Nagasaki Prefecture, Japan. Int J Hematol. 2007;85:132-. doi:10.1532/IJH97.06157 . CrossRef
8. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Tough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-. doi:10.1182/blood-2006-07-036012 . CrossRef
9. Larson RA, Drucker BJ, Guiihot F, O’Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-. doi:10.1182/blood-2007-10-116475 . CrossRef
10. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse M. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec? and its main metabolite (GCP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2002;768:325-0.
11. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-0. doi:10.1182/blood-2006-02-005686 . CrossRef
12. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879-4. doi:10.2165/00003088-200544090-00001 . CrossRef
13. Peng B, Hayes M, Resta D, Brian ARP, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935-2. doi:10.1200/JCO.2004.03.050 . CrossRef
14. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-1. doi:10.1056/NEJMoa055229 . CrossRef
15. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-1. doi:10.1056/NEJMoa055104 . CrossRef
16. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Giles F, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421-. doi:10.1182/blood-2006-02-001933 . CrossRef
17. Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsed S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-. CrossRef - 作者单位：Mari Sakai (1)
Yasushi Miyazaki (1)
Emi Matsuo (1)
Yukiyoshi Moriuchi (2)
Tomoko Hata (1)
Takuya Fukushima (1)
Yoshitaka Imaizumi (1)
Daisuke Imanishi (1)
Jun Taguchi (1)
Masako Iwanaga (1)
Hideki Tsushima (2)
Yoriko Inoue (2)
Yumi Takasaki (2)
Takeshi Tsuchiya (1)
Minori Komoda (1)
Koji Ando (1)
Kensuke Horio (1)
Yuji Moriwaki (2)
Shinya Tominaga (1)
Hidehiro Itonaga (1)
Kazuhiro Nagai (1)
Kunihiro Tsukasaki (1)
Chizuko Tsutsumi (2)
Yasushi Sawayama (2)
Reishi Yamasaki (2)
Daisuke Ogawa (2)
Yasuhisa Kawaguchi (2)
Shuichi Ikeda (2)
Shinichiro Yoshida (2)
Yasuyuki Onimaru (2)
Masayuki Tawara (2)
Sunao Atogami (2)
Satoshi Koida (2)
Tatsuro Joh (2)
Masaomi Yamamura (2)
Yuji Matsuo (2)
Hisashi Soda (2)
Hiroaki Nonaka (2)
Itsuro Jinnai (2)
Kazutaka Kuriyama (2)
Masao Tomonaga (1)
1. Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
2. Nagasaki CML Study Group, Nagasaki, Japan
文摘
Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6?years, and the cumulative complete cytogenetic response rate was 82.5% at 18?months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400?mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry.